NASDAQ:SILO Silo Pharma 3/27/2026 Earnings Report $0.41 +0.02 (+4.82%) As of 03:57 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Silo Pharma EPS ResultsActual EPS$0.03Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASilo Pharma Revenue ResultsActual Revenue$0.02 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASilo Pharma Announcement DetailsQuarterDate3/27/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Silo Pharma Earnings HeadlinesSilo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain InjuryMay 7, 2026 | globenewswire.comSilo Pharma, Inc.: Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 30, 2026 | finanznachrichten.deYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 15 at 1:00 AM | Profits Run (Ad)Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 30, 2026 | markets.businessinsider.comSilo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSDApril 29, 2026 | globenewswire.comSilo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, QwikagentsApril 22, 2026 | globenewswire.comSee More Silo Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silo Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silo Pharma and other key companies, straight to your email. Email Address About Silo PharmaSilo Pharma (NASDAQ:SILO) (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health. The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents. Key initiatives include research into treatments for chemotherapy-induced neurotoxicity, glioblastoma, neurodegenerative disorders and mood conditions such as depression and post-traumatic stress disorder. Silo Pharma leverages strategic collaborations and material licensing agreements with leading academic institutions to accelerate its research efforts. Originally founded as Elicio Therapeutics in 2019, the firm rebranded to Silo Pharma in 2021 to underscore its specialized focus on psychedelics and novel CNS therapies. In addition to its U.S. operations, the company engages in collaborative research activities with partners in Canada and Europe. Silo Pharma’s leadership team brings together expertise in pharmaceutical R&D, regulatory strategy and business development to position the company for growth in the emerging psychedelics sector.View Silo Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Datavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early InningsKarman: Defense Darling's Outlook Strengthens After 40% Drop Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
